Aphantasia, PTSD Intrusions, and Psychedelic Therapy: Implications for Trial Design

People with Aphantasia Experience Fewer PTSD Intrusions, Despite Comparable Distress

A large, peer-reviewed study published on November 11, 2026, in OpenAlex (W7225812102) found that individuals with aphantasia—an inability to voluntarily create mental images—reported significantly fewer intrusive memories after trauma exposure than those with typical imagery abilities. However, both groups experienced similar levels of overall distress, depression, anxiety, and arousal. This distinction is critical for understanding post-traumatic stress disorder (PTSD) mechanisms and for interpreting clinical outcomes in trauma research.

The study surveyed 340 adults with congenital aphantasia, 261 with vivid imagery from the same online communities, and 471 controls. All participants completed validated PTSD and trauma questionnaires, which the authors confirmed functioned equivalently across groups. At matched trauma exposure, those with aphantasia had about half the odds of reaching the PTSD screening cut-off compared to controls, largely due to fewer intrusive memories and less avoidance—but not less distress.

Mental Imagery's Role in Trauma Re-experiencing and Implications for Psychedelic Therapy

Mental imagery is a core feature of how trauma is re-experienced, but not necessarily how distressing it is. The study's findings suggest that while the vividness of mental imagery amplifies the frequency of intrusive memories—a hallmark symptom of PTSD—it does not mitigate the overall psychological impact of trauma. This nuance is especially relevant for psychedelic-assisted therapy, which often relies on imagery-rich experiences to process traumatic memories.

Psychedelic clinical trials for PTSD, such as those using MDMA or psilocybin, frequently emphasize the importance of visual and emotional imagery during therapy sessions. The new evidence indicates that individuals with low or absent imagery (aphantasia) may engage with these therapies differently, potentially experiencing fewer flashbacks or visual re-experiencing symptoms, but not necessarily less distress or impairment. This could affect both the subjective experience of therapy and the measurable outcomes in clinical trials.

Policy and Research Implications: Screening, Outcome Measures, and Equity

The discovery that aphantasia alters the symptom profile of PTSD without reducing distress has direct consequences for research design, regulatory review, and clinical practice. First, trial protocols may need to screen for imagery ability (using tools like the Vividness of Visual Imagery Questionnaire) to ensure balanced groups or to stratify analyses. Second, outcome measures that heavily weight intrusive imagery may underestimate trauma impact in aphantasic participants, potentially biasing results or masking treatment effects.

Regulators such as the U.S. Food and Drug Administration (FDA) and Health Canada may need to consider whether current PTSD diagnostic criteria and endpoint measures are sufficiently inclusive of neurodiverse populations. For psychedelic therapy developers and sponsors, this finding introduces a new variable for patient selection, trial interpretation, and post-approval monitoring. Notably, it suggests that low scores on standard PTSD checklists in aphantasic individuals do not necessarily indicate less harm or need for intervention.

• Trial Design: Consider stratifying or adjusting for imagery ability in psychedelic-assisted therapy studies.
• Outcome Interpretation: Recognize that standard PTSD metrics may not capture all forms of trauma-related distress.
• Access and Equity: Ensure that individuals with aphantasia are not excluded or mischaracterized in trauma research and care.

Risks, Unknowns, and Future Directions

Current evidence does not establish whether aphantasia confers any protective effect against the long-term consequences of trauma, nor does it clarify how these individuals respond to imagery-based interventions. There is also uncertainty about how psychedelic experiences unfold for people with aphantasia, as their capacity for internally generated imagery is limited. Some anecdotal reports suggest that psychedelics may temporarily enhance imagery, but systematic data are lacking.

Another risk is the potential for misdiagnosis or undertreatment. If clinicians rely solely on intrusive imagery as a marker of PTSD severity, they may overlook significant distress or impairment in aphantasic patients. This could have downstream effects on access to care, disability determinations, and clinical trial enrollment.

Looking Ahead: Personalizing Psychedelic and Trauma Therapies

Future research should prioritize understanding how individual differences in mental imagery affect both the phenomenology of trauma and the efficacy of psychedelic-assisted therapies. Incorporating imagery ability into trial screening and outcome assessment may improve both the validity and equity of research findings. For clinicians, recognizing that trauma-related distress can manifest without vivid flashbacks is essential for comprehensive care.

As the field moves toward personalized mental health interventions, this study underscores the need to account for neurodiversity—not just in diagnosis, but in treatment development and regulatory policy. The next wave of psychedelic research will need to address these subtleties to ensure that new therapies are both effective and inclusive.

Reviewed by Dr. Alex Morgan, PhD (Neuroscience), on 2026-11-12. Research based on primary source: OpenAlex W7225812102.